CDC revises reporting methodology for adverse drug reactions
On February 20, 2026, the U.S. Centers for Disease Control and Prevention announced revisions to its reporting methodology for adverse drug reactions (ADRs). The new approach updates data collection protocols to improve accuracy and timeliness of reporting.
Changes include the introduction of standardized electronic submission formats, expanded inclusion criteria for patient populations, and revised thresholds for reporting rare but serious reactions. The CDC stated that these adjustments are intended to reduce inconsistencies across states and reporting centers.
Public health analysts warned that historical data may not be directly comparable with new figures due to the revised methodology. Health providers and pharmaceutical companies are being instructed to follow updated submission guidelines beginning March 1, 2026.
The CDC emphasized that the changes are not linked to any specific drug safety concern but are part of an ongoing effort to enhance surveillance and strengthen public health response to adverse drug events.
